Author

E. Kerem

Observed name: Kerem, E.

Institutions: Hebrew University of Jerusalem, Hadassah Medical Center

Observed institutions: University of Alabama, Hebrew University of Jerusalem, Hadassah Medical Center, National Jewish Health, University of Alabama at Birmingham

OpenAlex ID: A5029327474

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

2020 · Knowles, M., Cuppens, H., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 50

PDF

619 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the W1282X nonsense mutation

2022 · O. Avizur Barchad, Y. Oren, et al. · Journal of Cystic Fibrosis · 3

PDF

WS06.06 Safety and efficacy of a nebulized phage cocktail in cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection: a phase 1b/2a randomized, double-blind, placebo-controlled study

2024 · E. Kerem, U. Rappo, et al. · Journal of Cystic Fibrosis · 2

126 A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study evaluating nebulized phage therapy in people with cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infection

2023 · U. Rappo, M. Kahan-Hanum, et al. · Journal of Cystic Fibrosis · 2

PDF

WS13.3 Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

2017 · M.W. Konstan, E. DiMango, et al. · Journal of Cystic Fibrosis · 2

PDF

WS06.05 Long-term outcomes in people with CF lacking early spirometry response to elexacaftor/tezacaftor/ivacaftor therapy

2024 · M. Hadhud, J. Reiter, et al. · Journal of Cystic Fibrosis · 1

133 Clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with the N1303K and non-modulator responsive mutation

2022 · I. Sadras, E. Kerem, et al. · Journal of Cystic Fibrosis · 1

PDF

Poster: 104SPL84 demonstrates clinically meaningful ppFEV1 improvement in people with cystic fibrosis carrying the 3849 +10 Kb C- >T mutation in ongoing Phase 2a study

2026 · S. Cofta, D. Springer, et al. · Journal of Cystic Fibrosis

Poster: 642Lung function trajectories following elexacaftor/tezacaftor/ivacaftor therapy: Analysis of the ECFS patient registry

2026 · O. Breuer, A. Orenti, et al. · Journal of Cystic Fibrosis

Poster: 287Identity-by-descent analysis of CFTR in Israeli Ashkenazi Jews and Karachays reveals shared ancestral haplotype

2026 · B. Newton, S. Mastromatteo, et al. · Journal of Cystic Fibrosis

Poster: 235SPL23, an exon-skipping antisense oligonucleotide for pwCF carrying the W1282X variant

2026 · Y. Cheng, Y. Oren, et al. · Journal of Cystic Fibrosis

Rationale and design of a Phase 2b study in people with cystic fibrosis carrying the 3849 +10 Kb C->T mutation to evaluate the combined effect of SPL84 and CFTR modulators

2026 · L. Friedman, E. Kerem, et al. · Journal of Cystic Fibrosis

SPL84 demonstrates clinically meaningful ppFEV1 improvement in people with cystic fibrosis carrying the 3849 +10 Kb C->T mutation in a Phase 2a study

2026 · S. Cofta, D. Springer, et al. · Journal of Cystic Fibrosis

Lung function trajectories in the era of highly effective CFTR modulator therapy: analysis of the ECFS patient registry

2026 · O. Breuer, A. Orenti, et al. · Journal of Cystic Fibrosis

10 Safety and efficacy of nebulized phage in people with cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study

2024 · U. Rappo, I. Maimon, et al. · Journal of Cystic Fibrosis

P095 A phase 1b/2a randomized, double-blind, placebo-controlled, multicentre study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aeruginosa pulmonary infection

2023 · U. Rappo, M. Kahan-Hanum, et al. · Journal of Cystic Fibrosis

PDF

615 Antisense oligonucleotide-based drug development for people with cystic fibrosis carrying the 2789+5 G-to-A splicing mutation

2022 · Y. Oren, O. Avizur Barchad, et al. · Journal of Cystic Fibrosis

PDF

620 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the N1303 K nonsense mutation

2022 · Y. Oren, O. Barchad-Avizur, et al. · Journal of Cystic Fibrosis

PDF

P088 Ventilation inhomogeneity in patients with cystic fibrosis and pancreatic sufficiency and insufficiency

2022 · O. Breuer, I. Akvian, et al. · Journal of Cystic Fibrosis

P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation

2022 · Y.S. Oren, O. Avizur Barchad, et al. · Journal of Cystic Fibrosis

P028 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis (CF) therapeutic approach for the W1282X nonsense mutation

2022 · O. Avizur Barchad, Y.S. Oren, et al. · Journal of Cystic Fibrosis

Works count: 21

Citation count: 61

H-index: 2

I10-index: 1